Related Experiment Video
Updated: Dec 31, 2025
Assays for Validating Histone Acetyltransferase Inhibitors
Published on: August 6, 2020
In silico Design of Novel Histone Deacetylase 4 Inhibitors: Design Guidelines for Improved Binding Affinity
Shana V Stoddard1, Kyra Dodson2, Kamesha Adams3
1Department of Chemistry, Natural Sciences Division, Rhodes College, 2000 North Parkway, Memphis, TN 38112, USA.
Abstract:
Histone deacetylases (HDAC) are being targeted for a number of diseases such as cancer, inflammatory disease, and neurological disorders. Within this family of 18 isozymes, HDAC4 is a prime target for glioma, one of the most aggressive brain tumors reported. Thus, the development of HDAC4 inhibitors could present a novel therapeutic route for glioma. In this work, molecular docking studies on cyclopropane hydroxamic acid derivatives identified five novel molecular interactions to the HDAC4 receptor that could be harnessed to enhance inhibitor binding. Thus, design guidelines for the optimization of potent HDAC4 inhibitors were developed which can be utilized to further the development of HDAC4 inhibitors. Using the developed guidelines, eleven novel cyclopropane hydroxamic acid derivatives were designed that outcompeted all original cyclopropane hydroxamic acids HDAC4 inhibitors studied in silico. The results of this work will be an asset to paving the way for further design and optimization of novel potent HDAC4 inhibitors for gliomas.
Insights
Researchers developed new guidelines for designing HDAC4 inhibitors, crucial for treating aggressive gliomas. Novel compounds designed using these guidelines show improved efficacy in silico, offering a promising therapeutic strategy.
Area of Science:
- Medicinal Chemistry
- Molecular Biology
- Oncology
Background:
- Histone deacetylases (HDACs) are therapeutic targets for various diseases, including cancer, inflammatory, and neurological disorders.
- HDAC4 is a key target for glioma, a highly aggressive brain tumor.
- Developing specific HDAC4 inhibitors offers a novel therapeutic approach for glioma treatment.
Purpose of the Study:
- To identify novel molecular interactions for enhancing HDAC4 inhibitor binding.
- To develop design guidelines for optimizing potent HDAC4 inhibitors.
- To design and evaluate novel cyclopropane hydroxamic acid derivatives as potential HDAC4 inhibitors for glioma.
Main Methods:
- Molecular docking studies were performed on cyclopropane hydroxamic acid derivatives against the HDAC4 receptor.
- Design guidelines were established based on identified molecular interactions.
- Eleven new cyclopropane hydroxamic acid derivatives were designed using the developed guidelines.
Main Results:
- Five novel molecular interactions targeting the HDAC4 receptor were identified.
- Design guidelines for optimizing HDAC4 inhibitors were successfully developed.
- The eleven newly designed derivatives demonstrated superior in silico inhibitory activity compared to original compounds.
Conclusions:
- The developed design guidelines are effective for optimizing HDAC4 inhibitors.
- Novel cyclopropane hydroxamic acid derivatives show significant potential as HDAC4 inhibitors for glioma.
- This work paves the way for the development of potent HDAC4 inhibitors for glioma therapy.
Related Concept Videos
01:30Enzyme Inhibition
01:28Structure-Activity Relationships and Drug Design
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...